logo

Aptevo Therapeutics Inc (APVO)



Trade APVO now with
  Date
  Headline
11/28/2017 7:03:22 AM Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma
8/10/2017 9:04:50 AM Aptevo Therapeutics Q2 Loss Per Share $0.53 Vs Loss $0.63 Last Year
5/12/2017 9:03:36 AM Aptevo Therapeutics Q1 Loss Per Share $0.48 Vs Loss $0.64 Prior Year
3/31/2017 9:06:22 AM Aptevo Therapeutics 2016 Net Loss $112.4 Mln Or $5.55/shr Vs. Loss $59.3 Mln Or $2.93/shr Prior Year
3/15/2017 8:34:36 AM Aptevo Therapeutics Reports New IXINITY Supply Available May 2017